BioSpace News Archive

Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release.

4BIO Capital, an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, announces that its portfolio company Entact Bio has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developing enhancement-targeting chimeric molecules.

Invea Therapeutics, Inc. today announced the appointment of Mr. Jason Fenton to its Board of Directors.

Novian Health has received Frost & Sullivan’s 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase® Breast Therapy system.

MyMD Pharmaceuticals, Inc. is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Ajax Therapeutics, Inc. today announced the appointment of Srdan “Serge” Verstovsek, MD, PhD, to the Company’s Scientific Advisory Board (SAB).

Bluestar Genomics, Inc. announced the initiation of the New Onset Diabetes Management for Earlier Detection (NODMED) trial, one of the largest clinical studies in pancreatic cancer to date.

Generate Biomedicines today announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer.

Verge Genomics announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.

Beginning , the 2022 Milken Institute Future of Health Summit will convene in-person for the first time since 2019.